News
-
-
-
PRESS RELEASE
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS
Theranexus and Exeltis sign license agreement for TX01, expanding treatment for rare neurological diseases. Exeltis to market TX01 across Europe and other regions -
-
-
-
PRESS RELEASE
BTQ Technologies Appoints Radical Semiconductor Founders to Advance Commercialization of Post-Quantum Semiconductors
BTQ Technologies appoints radical semiconductor founders and senior advisor to accelerate commercialization of post-quantum semiconductors, reinforcing leadership in quantum-era solutions -
-
-